The FDA approval of Merck’s PD-1 inhibitor Keytruda (pembrolizumab) for first-line treatment of non-small cell lung cancer is the start of a new treatment paradigm for lung cancer that will have broad effects on the competitive landscape.
Merck announced a two-part approval late Oct. 24. First, FDA approved Keytruda for first-line treatment of patients with metastatic non-small...